曼月乐对乳腺癌复发或转移风险的Meta分析

王雅楠; 卢雯平; 梅荷婷; 崔永佳; 卓至丽

doi:10.3971/j.issn.1000-8578.2022.21.1536

曼月乐对乳腺癌复发或转移风险的Meta分析

Risk of Recurrence or Metastasis of Breast Cancer by LNG-IUS: A Meta-analysis

摘要

摘要:
目的 Meta分析系统评价曼月乐对乳腺癌患者的复发或转移风险。
方法计算机检索PubMed、Web of Science、Cochrane、Embase、CBM、中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、万方数据知识服务平台等。检索年限为2004年1月-2021年10月, 对纳入的随机对照研究(RCT)文献进行数据提取和质量评价, 分析曼月乐是否会增加乳腺癌的复发或转移风险。
结果共检索到中英文文献1 309篇, 5篇RCT被纳入, 300例患者入组。固定效应模型进行总效应值合并, 合并RD为0.03(95% CI: -0.03~0.08, Z=1.05, P=0.29), 提示与单纯他莫昔芬(TAM)组相比, 曼月乐+他莫昔芬组未增加乳腺癌复发或转移风险。漏斗图提示发表偏倚较小。
结论佩戴曼月乐未明显增加乳腺癌患者复发或转移风险, 对乳腺癌患者具有一定的安全性。

Abstract:
Objective To evaluate the risk of recurrence or metastasis of breast cancer by LNG-IUS via meta-analysis.
Methods We searched literature in the PubMed, Web of Science, Cochrane, EMBASE, CBM, CNKI, VIP, and WanFang database.The retrieval period was from January 2014 to October 2021.Data extraction and quality evaluation were conducted for the included randomized controlled study (RCT) to analyze whether LNG-IUS can increase the risk of recurrence or metastasis of breast cancer.
Results A total of 1309 Chinese and English studies were retrieved; 5 RCTs were included in this study, and 446 patients were enrolled.The combined total effect value in the fixed-effect model with RD (95%CI)0.03(-0.03-0.08), Z=1.05, P=0.29) indicated that the LNG-IUS+tamoxifen group did not increase the risk of recurrence or metastasis of breast cancer compared with the tamoxifen group.The funnel diagram was basically symmetrical, suggesting that the publication bias was small.
Conclusion Wearing the LNG-IUS does not increase the risk of relapse or metastasis of breast cancer significantly, and it provides certain safety for patients with breast cancer.

HTML全文

参考文献(18)

施引文献

资源附件(0)